Physician profile
Jeffrey Bernstein
NPI 1861497422
$932.68
in general payments reported to CMS, 2019-2025
13 companies · $79.10 in 2025
The $79.10 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.07 · 2020: $27.57 · 2021: $78.49 · 2023: $208 · 2024: $519 · 2025: $79.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.18 | 2023-2025 | Skyrizi, Rinvoq |
| Gilead Sciences, INC. | $106.81 | 2023-2024 | |
| Celgene Corporation | $105.55 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.35 | 2020-2023 | Xifaxan |
| Genzyme Corporation | $54.57 | 2025 | |
| Janssen Biotech, INC. | $51.68 | 2024 | Stelara |
| Madrigal Pharmaceuticals | $35.94 | 2024 | Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $29.84 | 2024 | Entyvio |
| Pfizer INC. | $21.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.76 | 2024 | Voquezna |
| Redhill Biopharma INC. | $16.87 | 2021 | |
| Medtronic Vascular, INC. | $14.57 | 2020 | |
| Capsovision, INC. | $13.49 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.